Clinical trials: Diabetic Macular Edema
Age-related Macular Degeneration, Central Retinal Vein Occlusion
Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Since 2004, intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema are being administered in the United States at increasing rates.
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01640171
- Testing
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Retina Vitreous Associates of Florida
Diabetic Macular Edema
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema
This study is an interventional, prospective randomized study comparing the dexamethasone implant to intravitreal aflibercept. Subjects will have an initial single injection of aflibercept and will be randomized if diabetic…
- Trial name
- PRECISION (NCT04411693)
- Testing
- Dexamethasone implant, Aflibercept
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Diabetic Macular Edema
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
- Trial name
- NCT03097068
- Testing
- Lucentis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vitreo-Retinal Associates, Michigan
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Diabetic Retinopathy, Diabetic Eye Problems
Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more.
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04805541
- Testing
- Color Fundus Photography, Mydriatic Agent, EyeCheckup - AI Based DR Screening
- Where
- Turkey (Türkiye)
- Volunteers
- 900 people
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Macular Edema
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
To explore a more clinical feasible treatment regime with ranibizumab for DME to provide satisfactory treatment effect with a lower number of visits and injections.
- Trial name
- SALUTE-D (NCT02262260)
- Testing
- Labeled regime arm, Wait and Extend regime arm
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Diabetic Retinopathy
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
- Trial name
- NCT06181227
- Testing
- AVD-104
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aviceda Therapeutics, Inc.
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate the safety and efficacy of 4 dose cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).
- Trial name
- NCT05301751
- Testing
- AG-73305
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allgenesis Biotherapeutics Inc.
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Diabetic Macular Edema
Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Currently, two similar medications are available for injection into the eye to treat a variety of eye diseases. These medications are called ranibizumab (Lucentis) and bevacizumab (Avastin).
- Trial name
- NCT01661946
- Testing
- Bevacizumab, Ranibizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Queen's University
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Diabetic Macular Edema
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009; NCT01363440) end-point.
- Trial name
- NCT02299336
- Testing
- Aflibercept, Focal Laser
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Greater Houston Retina Research
Macular Edema
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision…
- Trial name
- NCT02732951
- Testing
- BI 1026706
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative…
- Trial name
- ROBIN (NCT03238963)
- Testing
- BI 1467335
- Where
- 35 sites in United States, Austria and 6 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Nonproliferative Diabetic Retinopathy
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Title of study: Effects of Ranibizumab to delay or regression non-proliferative diabetic retinopathy(NPDR) with DME assessed by microaneurysm changes: A pilot study Objectives Diabetic retinopathy (DR) is a major cause of visual…
- Trial name
- NCT02834663
- Testing
- Lucentis
- Volunteers
- 25 people
- Sponsor
- Wonkwang University Hospital
Diabetic Macular Edema
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
The study involves the enrollment of patients over 18 years of age with diabetic macular edema involving the center of the macula who have not already been given maximal laser treatment.
- Trial name
- Peribulbar (NCT00369486)
- Testing
- Focal laser photocoagulation, 40mg triamcinolone, 20mg triamcinolone
- Volunteers
- 113 people
- Sponsor
- Jaeb Center for Health Research
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research